tiprankstipranks
Trending News
More News >
Formycon AG (DE:FYB)
:FYB
Advertisement

Formycon AG (FYB) AI Stock Analysis

Compare
30 Followers

Top Page

DE:FYB

Formycon AG

(XETRA:FYB)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - 4o)
Rating:54Neutral
Price Target:
€26.00
▲(2.36% Upside)
Formycon AG's overall stock score is primarily influenced by its mixed financial performance, with strengths in balance sheet stability but significant challenges in profitability and cash flow. Technical analysis indicates a bearish trend, and valuation metrics are weak due to negative profitability and lack of dividend yield. These factors collectively result in a moderate overall score.
Positive Factors
Balance Sheet Stability
A strong equity base and low debt-to-equity ratio indicate financial resilience, providing the company with stability to weather economic fluctuations.
Strategic Partnerships
Strategic partnerships enhance market reach and provide revenue stability through upfront, milestone, and royalty payments, supporting long-term growth.
Operational Efficiency
Strong EBITDA performance suggests efficient operations, which can lead to improved profitability and competitiveness in the long term.
Negative Factors
Declining Revenue Growth
Declining revenue growth can hinder the company's ability to invest in R&D and expand its biosimilar portfolio, impacting future competitiveness.
Negative Cash Flow
Consistently negative cash flow from operations can strain liquidity and limit the company's ability to fund new projects or manage unexpected expenses.
Profitability Challenges
Negative profitability metrics indicate difficulty in converting revenue into profit, which can affect long-term financial health and investor confidence.

Formycon AG (FYB) vs. iShares MSCI Germany ETF (EWG)

Formycon AG Business Overview & Revenue Model

Company DescriptionFormycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
How the Company Makes MoneyFormycon AG generates revenue through the development and commercialization of biosimilar products. The company primarily earns money by entering into partnerships and licensing agreements with larger pharmaceutical companies that market and distribute Formycon's biosimilar drugs. These partnerships often involve upfront payments, milestone payments based on development and regulatory achievements, and royalty payments based on sales of the biosimilars. Additionally, Formycon invests in its own pipeline of biosimilars, which, upon successful commercialization, contribute to its revenue streams. The company's strategic collaborations and licensing agreements are crucial for its financial performance, enabling it to leverage the distribution networks and market reach of its partners.

Formycon AG Financial Statement Overview

Summary
Formycon AG exhibits a mixed financial performance with strong balance sheet stability, reflected by a healthy equity ratio and low leverage. However, challenges in profitability and cash flow generation are significant concerns. The company's reliance on external financing for cash flow is a potential risk.
Income Statement
62
Positive
Formycon AG demonstrates volatile revenue trends with a notable decline from 2023 to 2024. The company faces profitability challenges, evidenced by negative EBIT and net income margins in 2024. Despite this, the company experienced strong EBITDA performance in 2023, indicating potential operational efficiency. However, the negative net profit margin and declining revenue growth are areas of concern.
Balance Sheet
75
Positive
The company's balance sheet shows a strong equity base with a healthy equity ratio, reflecting financial stability. The debt-to-equity ratio is low, suggesting conservative leverage usage. However, the declining stockholders' equity from 2023 to 2024 could indicate potential risk. Return on equity is negative in 2024 due to net losses, which is a downside.
Cash Flow
58
Neutral
Operating cash flows are consistently negative, highlighting challenges in generating cash from operations. Free cash flow is also negative, which may affect liquidity. Despite negative cash flows, the company has managed to improve its cash position through financing activities, which could provide short-term relief.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue51.78M69.67M77.70M42.50M36.61M34.23M
Gross Profit-514.00K14.83M23.30M12.07M10.11M-2.19M
EBITDA-115.52M-4.10M81.05M51.53M-12.42M-4.92M
Net Income-169.77M-125.67M75.80M35.99M-13.29M-6.73M
Balance Sheet
Total Assets742.56M771.72M890.36M853.70M70.72M75.60M
Cash, Cash Equivalents and Short-Term Investments27.29M41.84M27.04M9.82M25.18M42.25M
Total Debt10.21M10.59M29.49M49.31M5.28M5.96M
Total Liabilities334.23M309.87M387.61M497.12M14.82M7.56M
Stockholders Equity408.33M461.84M502.75M356.58M55.89M68.04M
Cash Flow
Free Cash Flow13.75M-53.16M-10.88M-45.75M-14.48M-5.86M
Operating Cash Flow14.48M-23.22M-9.85M-18.99M-13.54M-5.21M
Investing Cash Flow-7.26M-1.46M-17.38M-37.07M-3.93M-650.00K
Financing Cash Flow-20.75M39.48M44.44M40.85M491.00K25.75M

Formycon AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price25.40
Price Trends
50DMA
24.22
Positive
100DMA
25.84
Negative
200DMA
30.76
Negative
Market Momentum
MACD
0.24
Negative
RSI
62.62
Neutral
STOCH
81.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FYB, the sentiment is Positive. The current price of 25.4 is above the 20-day moving average (MA) of 23.17, above the 50-day MA of 24.22, and below the 200-day MA of 30.76, indicating a neutral trend. The MACD of 0.24 indicates Negative momentum. The RSI at 62.62 is Neutral, neither overbought nor oversold. The STOCH value of 81.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FYB.

Formycon AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
€374.40M19.4952.68%0.16%15.20%6.77%
67
Neutral
€385.95M24.096.73%1.88%-1.64%22.60%
66
Neutral
$372.38M19.783.56%7.02%10.58%
59
Neutral
€1.35B44.96-4.72%0.14%-18.82%-113.85%
55
Neutral
€1.35B64.15-4.72%0.11%-18.82%-113.85%
54
Neutral
€454.19M5.89-34.48%-14.84%-338.52%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:FYB
Formycon AG
25.40
-26.90
-51.43%
DE:BIO
Biotest
38.00
-3.40
-8.21%
DE:BIO3
Biotest
30.00
2.14
7.68%
DE:SBS
STRATEC Biomedical
32.00
-9.35
-22.62%
DE:ILM1
Medios AG
14.80
0.10
0.68%
DE:PSG
PharmaSGP Holding SE
31.20
7.84
33.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 04, 2025